HRP20180776T1 - Antagonisti il17c za liječenje upalnih poremećaja - Google Patents
Antagonisti il17c za liječenje upalnih poremećaja Download PDFInfo
- Publication number
- HRP20180776T1 HRP20180776T1 HRP20180776TT HRP20180776T HRP20180776T1 HR P20180776 T1 HRP20180776 T1 HR P20180776T1 HR P20180776T T HRP20180776T T HR P20180776TT HR P20180776 T HRP20180776 T HR P20180776T HR P20180776 T1 HRP20180776 T1 HR P20180776T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- lcdr2
- lcdr1
- lcdr3
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims 3
- 239000005557 antagonist Substances 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 17
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 17
- 101000998178 Homo sapiens Interleukin-17C Proteins 0.000 claims 9
- 102100033105 Interleukin-17C Human genes 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 101001019590 Homo sapiens Interleukin-17 receptor E Proteins 0.000 claims 1
- 102100035016 Interleukin-17 receptor E Human genes 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (7)
1. Izolirano antitijelo ili fragment antitijela specifičan za IL17C, naznačen time, što se upotrebljava za liječenje upalnog poremećaja, gdje je navedeni upalni poremećaj upala pluća, reumatoidni artritis i/ili kronična opstruktivna bolest pluća (COPD), pri čemu se IL17C sastoji od amino-kiselina SEQ. ID br.: 181, i gdje navedeno antitijelo blokira vezivanje IL17C za IL17RE.
2. Izolirano antitijelo ili fragment antitijela specifičan za IL17C za uporabu prema patentnom zahtjevu 1, naznačen time, što navedeno antitijelo ili fragment antitijela unakrsno konkurira s antitijelom ili fragmentom antitijela koji sadrži 6 CDR definiranih po Kabat-u, koji se bira između antitijela ili fragmenta antitijela koji sadrži
HCDR1 Seq. ID: 1, HCDR2 Seq. ID: 2, HCDR3 Seq. ID: 3, LCDR1 Seq. ID: 4, LCDR2 Seq. ID: 5 i LCDR3 Seq. ID: 6 (MOR12740), ili
HCDR1 Seq. ID: 31, HCDR2 Seq. ID: 32, HCDR3 Seq. ID: 33, LCDR1 Seq. ID: 34, LCDR2 Seq. ID: 35 i LCDR3 Seq. ID: 36 (MOR12743), ili
HCDR1 Seq. ID: 41, HCDR2 Seq. ID: 42, HCDR3 Seq. ID: 43, LCDR1 Seq. ID: 44, LCDR2 Seq. ID: 45 i LCDR3 Seq. ID: 46 (MOR12744), ili
HCDR1 Seq. ID: 51, HCDR2 Seq. ID: 52, HCDR3 Seq. ID: 53, LCDR1 Seq. ID: 54, LCDR2 Seq. ID: 55 i LCDR3 Seq. ID: 56 (MOR12745), ili
HCDR1 Seq. ID: 61, HCDR2 Seq. ID: 62, HCDR3 Seq. ID: 63, LCDR1 Seq. ID: 64, LCDR2 Seq. ID: 65 i LCDR3 Seq. ID: 66 (MOR12746), ili
HCDR1 Seq. ID: 71, HCDR2 Seq. ID: 72, HCDR3 Seq. ID: 73, LCDR1 Seq. ID: 74, LCDR2 Seq. ID: 75 i LCDR3 Seq. ID: 76 (MOR12751), ili
HCDR1 Seq. ID: 91, HCDR2 Seq. ID: 92, HCDR3 Seq. ID: 93, LCDR1 Seq. ID: 94, LCDR2 Seq. ID: 95 i LCDR3 Seq. ID: 96 (MOR12754), ili
HCDR1 Seq. ID: 141, HCDR2 Seq. ID: 142, HCDR3 Seq. ID: 143, LCDR1 Seq. ID: 144, LCDR2 Seq. ID: 145 i LCDR3 Seq. ID: 146 (MOR12759), ili
HCDR1 Seq. ID: 151, HCDR2 Seq. ID: 152, HCDR3 Seq. ID: 153, LCDR1 Seq. ID: 154, LCDR2 Seq. ID: 155 i LCDR3 Seq. ID: 156 (MOR12760), ili
HCDR1 Seq. ID: 161, HCDR2 Seq. ID: 162, HCDR3 Seq. ID: 163, LCDR1 Seq. ID: 164, LCDR2 Seq. ID: 165 i LCDR3 Seq. ID: 166 (MOR12761), ili
HCDR1 Seq. ID: 171, HCDR2 Seq. ID: 172, HCDR3 Seq. ID: 173, LCDR1 Seq. ID: 174, LCDR2 Seq. ID: 175 i LCDR3 Seq. ID: 176 (MOR12762).
3. Izolirano antitijelo ili fragment antitijela specifičan za IL17C za uporabu iz patentnog zahtjeva 1 ili 2, naznačen time, što je navedeno antitijelo ili njegov fragment monoklonsko antitijelo.
4. Antitijelo ili fragment antitijela specifičan za IL17C za uporabu iz patentnog zahtjeva 3, naznačen time, što je navedeno antitijelo ili fragment antitijela humano, humanizirano ili himerno antitijelo ili fragment antitijela.
5. Antitijelo ili fragment antitijela specifičan za IL17C za uporabu iz patentnog zahtjeva 3, naznačen time, što navedeno antitijelo ili fragment antitijela sadrži humano teškolančano konstantno područje i humano lakolančano konstantno područje.
6. Antitijelo ili fragment antitijela specifičan za IL17C za uporabu iz patentnog zahtjeva 3, naznačen time, što je navedeno antitijelo IgG izotipa.
7. Antitijelo ili fragment antitijela specifičan za IL17C za uporabu iz patentnog zahtjeva 3, naznačen time, što se fragment antitijela bira iz grupe koja se sastoji od Fab, F(ab2)’, F(ab)2’, scFV.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548744P | 2011-10-19 | 2011-10-19 | |
| EP11185763 | 2011-10-19 | ||
| PCT/EP2012/070736 WO2013057241A1 (en) | 2011-10-19 | 2012-10-19 | Antagonists of il17c for the treatment of inflammatory disorders |
| EP12775247.5A EP2768859B1 (en) | 2011-10-19 | 2012-10-19 | Antagonists of il17c for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180776T1 true HRP20180776T1 (hr) | 2018-08-10 |
Family
ID=48140378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180776TT HRP20180776T1 (hr) | 2011-10-19 | 2018-05-18 | Antagonisti il17c za liječenje upalnih poremećaja |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20140243506A1 (hr) |
| EP (2) | EP3360897A1 (hr) |
| JP (1) | JP2014530836A (hr) |
| CN (1) | CN103974976A (hr) |
| AU (1) | AU2012324895B2 (hr) |
| CA (1) | CA2852145C (hr) |
| CY (1) | CY1120219T1 (hr) |
| DK (1) | DK2768859T3 (hr) |
| ES (1) | ES2669984T3 (hr) |
| HR (1) | HRP20180776T1 (hr) |
| HU (1) | HUE037087T2 (hr) |
| LT (1) | LT2768859T (hr) |
| ME (1) | ME03073B (hr) |
| MX (1) | MX360710B (hr) |
| PL (1) | PL2768859T3 (hr) |
| PT (1) | PT2768859T (hr) |
| RS (1) | RS57209B1 (hr) |
| SG (1) | SG11201401202YA (hr) |
| SI (1) | SI2768859T1 (hr) |
| TR (1) | TR201807056T4 (hr) |
| WO (1) | WO2013057241A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0913578A2 (pt) | 2008-05-14 | 2017-06-06 | Dermtech Int | diagnose de melanoma e lentigo solar por análise de ácido nucléico |
| WO2012061129A1 (en) * | 2010-10-25 | 2012-05-10 | Genentech, Inc | Treatment of gastrointestinal inflammation and psoriasis a |
| WO2016096896A1 (en) * | 2014-12-15 | 2016-06-23 | Morphosys Ag | Antibodies for il-17c |
| RU2018114657A (ru) | 2015-10-05 | 2019-11-07 | МорфоСис АГ | Антагонисты IL-17C для лечения и/или предупреждения атопического дерматита |
| TW201734041A (zh) * | 2016-02-19 | 2017-10-01 | 莫菲西斯公司 | 抗ｉｌ-１７ｃ抗體 |
| AU2017259966A1 (en) * | 2016-05-03 | 2018-11-22 | The Scripps Research Institute | TrkB agonist antibodies for treating neurodegenerative disorders |
| US20230203149A1 (en) | 2017-09-25 | 2023-06-29 | Morphosys Ag | Treatment of atopic dermatitis |
| CA3090785A1 (en) | 2018-02-14 | 2019-08-22 | John Daniel Dobak Iii | Novel gene classifiers and uses thereof in non-melanoma skin cancers |
| GB201803563D0 (en) | 2018-03-06 | 2018-04-18 | Galapagos Nv | Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases |
| EP3813678A4 (en) * | 2018-05-09 | 2022-06-08 | Dermtech, Inc. | NOVEL GENE CLASSIFIERS AND USES THEREOF IN AUTOIMMUNE DISEASES |
| US11578373B2 (en) | 2019-03-26 | 2023-02-14 | Dermtech, Inc. | Gene classifiers and uses thereof in skin cancers |
| KR20210087891A (ko) * | 2019-12-30 | 2021-07-13 | 경상국립대학교병원 | 박테리아 감염증 예방 또는 치료용 약학 조성물 |
| CN112795637A (zh) * | 2021-01-08 | 2021-05-14 | 孙洪臣 | 靶向il-17c的抑制剂在治疗炎症相关慢性肾脏疾病中的用途 |
| US20240230666A1 (en) * | 2021-03-25 | 2024-07-11 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing, and treating disturbed microbiota-immune homeostasis |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| PT1076703E (pt) | 1998-05-15 | 2007-10-10 | Genentech Inc | ''utilizações terapêuticas de polipéptido homólogos de il-17'' |
| EP1990409A3 (en) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bacteriophage |
| AU2590901A (en) * | 1999-12-23 | 2001-07-03 | Genentech Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
| US20040197306A1 (en) * | 2000-05-24 | 2004-10-07 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
| AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| BRPI0516603A (pt) * | 2004-10-18 | 2008-09-16 | Zymogenetics Inc | receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos para tratar uma doença imuno-mediada em um paciente em necessidade de tal tratamento, para reduzir a inflamação mediada pela il-17c, para tratar um mamìfero afligido com uma doença inflamatória, e para tratar uma condição patológica em um paciente associada com a atividade de zcytor21 |
| WO2007047738A1 (en) * | 2005-10-18 | 2007-04-26 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
| CA2666842A1 (en) * | 2006-10-18 | 2008-04-24 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
| CA2707026C (en) * | 2007-12-07 | 2017-04-11 | Zymogenetics, Inc. | Anti-human il-21 monoclonal antibodies |
| WO2009132821A1 (en) * | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
| US20130064788A1 (en) * | 2009-10-10 | 2013-03-14 | Eleven Biotherapeutics, Inc. | Il-17 family cytokine compositions and uses |
| WO2012061129A1 (en) * | 2010-10-25 | 2012-05-10 | Genentech, Inc | Treatment of gastrointestinal inflammation and psoriasis a |
| US20140234330A1 (en) * | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
-
2012
- 2012-10-19 JP JP2014536248A patent/JP2014530836A/ja active Pending
- 2012-10-19 EP EP18157106.8A patent/EP3360897A1/en not_active Withdrawn
- 2012-10-19 RS RS20180567A patent/RS57209B1/sr unknown
- 2012-10-19 EP EP12775247.5A patent/EP2768859B1/en active Active
- 2012-10-19 SG SG11201401202YA patent/SG11201401202YA/en unknown
- 2012-10-19 PL PL12775247T patent/PL2768859T3/pl unknown
- 2012-10-19 US US14/351,162 patent/US20140243506A1/en not_active Abandoned
- 2012-10-19 ES ES12775247.5T patent/ES2669984T3/es active Active
- 2012-10-19 CA CA2852145A patent/CA2852145C/en active Active
- 2012-10-19 SI SI201231302T patent/SI2768859T1/en unknown
- 2012-10-19 AU AU2012324895A patent/AU2012324895B2/en active Active
- 2012-10-19 WO PCT/EP2012/070736 patent/WO2013057241A1/en active Application Filing
- 2012-10-19 TR TR2018/07056T patent/TR201807056T4/tr unknown
- 2012-10-19 DK DK12775247.5T patent/DK2768859T3/en active
- 2012-10-19 LT LTEP12775247.5T patent/LT2768859T/lt unknown
- 2012-10-19 MX MX2014004662A patent/MX360710B/es active IP Right Grant
- 2012-10-19 PT PT127752475T patent/PT2768859T/pt unknown
- 2012-10-19 CN CN201280051378.3A patent/CN103974976A/zh active Pending
- 2012-10-19 ME MEP-2018-135A patent/ME03073B/me unknown
- 2012-10-19 HU HUE12775247A patent/HUE037087T2/hu unknown
-
2018
- 2018-05-16 CY CY20181100504T patent/CY1120219T1/el unknown
- 2018-05-18 HR HRP20180776TT patent/HRP20180776T1/hr unknown
- 2018-11-08 US US16/184,390 patent/US10815297B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2669984T3 (es) | 2018-05-29 |
| SI2768859T1 (en) | 2018-06-29 |
| HUE037087T2 (hu) | 2018-08-28 |
| AU2012324895A1 (en) | 2014-04-17 |
| CA2852145A1 (en) | 2013-04-25 |
| CN103974976A (zh) | 2014-08-06 |
| US20140243506A1 (en) | 2014-08-28 |
| EP2768859A1 (en) | 2014-08-27 |
| EP2768859B1 (en) | 2018-02-21 |
| MX2014004662A (es) | 2015-06-02 |
| PT2768859T (pt) | 2018-05-23 |
| CA2852145C (en) | 2021-01-12 |
| SG11201401202YA (en) | 2014-06-27 |
| PL2768859T3 (pl) | 2018-07-31 |
| CY1120219T1 (el) | 2018-12-12 |
| RS57209B1 (sr) | 2018-07-31 |
| US10815297B2 (en) | 2020-10-27 |
| DK2768859T3 (en) | 2018-06-06 |
| EP3360897A1 (en) | 2018-08-15 |
| TR201807056T4 (tr) | 2018-06-21 |
| NZ623289A (en) | 2015-12-24 |
| JP2014530836A (ja) | 2014-11-20 |
| LT2768859T (lt) | 2018-06-11 |
| US20190062422A1 (en) | 2019-02-28 |
| WO2013057241A1 (en) | 2013-04-25 |
| AU2012324895B2 (en) | 2017-03-16 |
| ME03073B (me) | 2019-01-20 |
| MX360710B (es) | 2018-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180776T1 (hr) | Antagonisti il17c za liječenje upalnih poremećaja | |
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| HRP20171690T1 (hr) | Antitijela koja se vežu za humani cgrp receptor | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| RU2017128882A (ru) | Антитела к биотину и способы их применения | |
| JP2013198490A5 (hr) | ||
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| JP2016135783A5 (hr) | ||
| JP2015535828A5 (hr) | ||
| HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
| NZ718973A (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| RU2016125489A (ru) | Нейтрализующие моноклональные человеческие антитела против интерлейкина-33 | |
| HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
| NZ728874A (en) | Anti-pd-1 monoclonal antibody and obtaining method therefor | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RS53661B1 (en) | HIGH AFINITY ANTIBODY ANTIBODIES TO THE HUMAN NERVOUS FACTOR OF GROWTH | |
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| JP2017505125A5 (hr) | ||
| HRP20221471T1 (hr) | Protutijela anti-fgfr3 i postupci za njihovu uporabu | |
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| RS54685B1 (en) | ANTI-N3pGlu AMILOID BETA PEPTID ANTIBODIES AND THEIR USES | |
| RS52643B (en) | HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR | |
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof |